Already part of several collaborations for COVID-19 vaccine candidates, Gaithersburg-based Emergent BioSolutions announced Monday that it will manufacture a potential treatment for the coronavirus called lenzilumab. The drug, which is being developed by California-based Humanigen, Inc., is currently being tested in a phase 3 trial on hospitalized COVID-19 patients. It aims to prevent and treat “cytokine storm,” a severe, sometimes deadly, immune system reaction that can be caused by COVID-19.
Potential COVID-19 treatment will be manufactured in Baltimore
January 26, 2021